Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Recordati SpA
Limitations in the design of the clinical trials that were carried out for each drug are among the concerns highlighted by the health technology assessment body in two interim guidances that are now out for consultation.
The Italian firm's move to license Isturisa from Novartis last year is paying dividends already and Recordati has already tripled its peak sales forecast for the Cushing's therapy.
Premature ejaculation treatment Fortacin is set to become only the fifth drug to achieve an Rx-to-OTC switch through European Medicines Agency's centralized procedure, expanding the burgeoning OTC men's sexual health category.
- OTC, Consumer
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Bouchara Recordati
- Dr. F. Frik Ilaç A.S.
- Opalia Pharma S.A.
- Orphan Europe
- Recordati Pharmaceuticals Ltd.
- Laboratorios Casen Fleet
- Italchimici S.p.A.
- Pro Farma AG
- Recordati S.A. Chemical and Pharmaceutical Company
- Recordati Rare Diseases Canada Inc.
- Natural Point S.r.l.
- Tonipharm S.A.S.